Annual Meeting Daily - Saturday, April 13, 2024

Saturday, April 13, 2024

Sessions

AAN Vision

To be indispensable to our members

AAN Mission

To enhance member career fullfillment and promote brain health for all

American Academy of Neurology

201 Chicago Avenue

Minneapolis, MN 55415 USA

Phone: (800) 879-1960 (Toll Free) or (612) 928-6000 (International)

Fax: (612) 454-2744

Email: memberservices@aan.com

Website: AAN.com

AAN Chief Executive Officer: Mary E. Post, MBA, CAE

Managing Editor: Angela M. Babb, MS, CAE, APR

Editor: Sarah Parsons

Brain Foundation” is a registered service mark of the American Brain Foundation and is registered in the United States.

Fantastic Booths and Where to Find Them: Your Guide to the Grand Concourse

Visit booths in and near the Grand Concourse to connect with AAN staff, learn about key priorities and initiatives and how you can get involved, and get swag or the chance to win prizes! Learn about each booth below.

American Brain Foundation (Grand Concourse)

Learn about the American Brain Foundation’s purpose and impact and get information on 2025 grants and awards. Booth attendees can pick up a t-shirt and spin the wheel for other swag, donate to support brain disease research, and hear about the ABF’s “Cure One, Cure Many” program.

BrainPAC (Grand Concourse)

BrainPAC amplifies AAN advocacy on Capitol Hill and helps secure legislative and regulatory advances for neurology. Learn about BrainPAC’s work around streamlining prior authorization, bolstering the neurology workforce, fixing Medicare reimbursement, and more.

Neurology Career Center (Grand Concourse)

Do you know about the job search help available to you at the AAN? Learn about the Job Alert tool and other career resources—and pick up a pen, a t-shirt (while supplies last), the April job guide, and articles to rev up your job search.

Online Learning (Grand Concourse)

See how Annual Meeting On Demand can help you get even more out of the meeting and add it to your registration before the end of the meeting for up to 55% off the full price. Plus, learn about all our offerings and how to check off your CME requirements all year long with the AAN’s online learning programs and the new Online Learning Center!

Practice, Policy, and Advocacy (Lobby F)

Are you searching for ways to make your practice more successful, reduce administrative headaches, and fight burnout? Visit this booth to learn about practice management and health information tools that can help—and to see what AAN advocates are doing for you and your patients. While you’re there, pick up a brain pin or microfiber cloth wipe to show off your AAN pride.

Publications (Grand Concourse)

The AAN has nine different publications that can help you earn CME, keep up with the latest research, and help your patients and their families learn about brain health! Learn about AAN journals and magazines, get the scoop on an upcoming open access journal, get a sweet 15% discount on Continuum®: Lifelong Learning in Neurology, sign up for a giveaway, and browse products and swag.

That’s not all! While you check out the booths, you can read what your colleagues are saying about #AANAM and #NeurologyProud on the social media wall and stop by the Hydration Station to refill your water bottle.

Looking for something and haven’t found it? Visit Meeting Information near the Big Blue Bear to get your questions answered and be pointed in the direction of your next marvelous experience at the Annual Meeting.

Controversies in Neurology

Experts Debate Latest Controversial Issues in This Morning’s Plenary Session

Some of the most current and controversial issues in neurology will be debated during today’s lively Controversies in Neurology Plenary Session, which runs this morning from 9:00 a.m. to 11:00 a.m. in the Bellco Theatre. The session will showcase six experts engaged in a debate-style format that will see two speakers arguing one side of a single topic, followed by a rebuttal.

The session will be moderated by:

Rashmi B.

Halker

Singh, MD, FAAN Member, Science Committee

Chad

Hales,

MD, PhD, FAAN Member, Science Committee

AI Powered Automated EEG: Supervision Needed?

YES

Edilberto Amorim, MD University of California San Francisco, San Francisco, CA

NO

Cecil D. Hahn, MD

Which side are you on?

Join the conversation at #AANAM.

Alzheimer’s Disease: Is Amyloid Enough?

YES

Eric M. McDade, DO

Washington University School of Medicine, Saint Louis, MO

NO

David T. Jones, MD Mayo Clinic, Rochester, MN

Is a Picture Worth a Thousand Treatments: Treating the Silent Vascular Lesion?

YES

Eric E. Smith, MD University of Calgary, Calgary, AB, Canada

NO

Hugo Javier Aparicio, MD, MPH Boston University Medical Center, Boston, MA

The Hospital for Sick Children, Toronto, ON, Canada

Advances in Neurology Education Take Center Stage in Hot Topics Course

Start your day tomorrow with a thought-provoking Hot Topics seminar on technological advances, like artificial intelligence and virtual classes, that are transforming neurology education. Neurology Education: Hot Topics in Clinical Practice: Advances in Neurology Education will take place from 7:00 a.m. to 9:00 a.m. Sunday in Mile High 1BCD. The event is packed with interesting, informative speeches by course director David Wolf, MD, PhD; speaker Tamara B. Kaplan, MD; and speaker Christopher T. Doughty, MD, with time for a Q&A session at the end.

AAN Takes Sustainable, Earth-friendly Approach to Annual Meeting

Several sustainability initiatives are at play at the 2024 Annual Meeting.

The AAN is taking a digital-first approach to all promotional communications for the meeting, reducing the use of single-use materials like signs or printed brochures. For single-use materials that remain, compostable or environmentally friendly inks are used wherever possible (remember to recycle this issue of Annual Meeting Daily!) The AAN also looks for opportunities to repurpose excess materials from past meetings to reduce materials entering landfills. Other Earth-friendly measures are in place at the Colorado Convention Center itself. As well as stations that allow attendees to refill water bottles rather than buying single-use ones, the center has programs in energy reduction and alternative sources, waste reduction and diversion, water consumption and quality, air quality and alternative transportation, and community-building efforts such as donating leftover conference materials to local nonprofits. The center’s certifications include LEED Gold and ISO 14001.

To learn more about 2024 Annual Meeting sustainability efforts, visit AAN.com/AMFAQ.

Attend Today’s AAN Business Meeting

The annual Business Meeting of the American Academy of Neurology will be held today from 3:30 p.m. to 4:30 p.m. in room 205. The session will feature reports on 2023 activities and finances from President Carlayne E. Jackson, MD, FAAN; CEO Mary E. Post, MBA, CAE; and Treasurer Charles C. Flippen II, MD, FAAN.

Check out Continuum Audio, Now a Free Podcast—and Hear the Journal Come to Life

Looking for an informative and engaging podcast to listen to during your meeting downtime—or maybe during your flight home?

Continuum® Audio, which features interviews with the expert authors and guest editors of Continuum: Lifelong Learning in Neurology®, is available wherever you get your podcasts—no subscription or log-in needed.

The podcast brings Continuum® to life through conversations featuring clinical highlights from the issue and the personal stories behind it. AAN members can get free CME by listening to interviews and completing the evaluations at continpub.com/AudioCME.

Don’t forget to stop by the Continuum booth in the Grand Concourse in the Colorado Convention Center for a 15% discount on all subscriptions, even on top of the already-discounted AAN member price! AAN members pay just $339 a year with this deal. Subscribers to the journal get exclusive access to Continuum Audio interviews and CME and to Continuum® Aloud, verbatim audio-book style recordings of articles.

Show us you follow or subscribe to Continuum Audio for a giveaway with Continuum’s great artwork—available until the supply runs out!

Jackson Post Flippen

Wolf Kaplan Doughty

5

Daily Reminders

For easy access to meeting links, visit AAN.com/QuickLinks

Attendee Lunch

Attendee lunch is included in your registration fee and served from 11:00 a.m.–1:00 p.m. today in Bluebird 1AB. Lunches are served in compostable boxes to help the AAN’s sustainability efforts.

Want More Time to Review Programs?

Add Annual Meeting On Demand to your registration now to save up to 55% and extend your access to session recordings through March 1, 2025. Check the back of your badge to see if you already have Annual Meeting On Demand. If not, head to the Online Learning booth in the Grand Concourse or email aanamsupport@cmrus.com by May 6, 2024, to add it to your registration.

AANTV Studio

This week, stop by the AANTV Studio in Lobby D to witness live interviews being recorded for later broadcast on the online platform, TV monitors around the convention center, AAN.com, and YouTube. View preview video at AAN.com/AANTV.

Program Slides Available Online

Slides are available online only at AAN.com/Materials or through the AAN Conferences mobile app. You can access program materials through March 1, 2025. (Please note that availability of materials is at the discretion of the specific speaker. Not all sessions will have materials.)

Access Past Content with AAN Rewind

Conference attendees have access to content on AAN Rewind through May 6, 2024. Visit AAN.com/AMOnline and use your 6-digit ID and password to log in. It may take up to 48 hours after course completion for content to become available on AAN Rewind.

View all conference guidelines at AAN.com/ConfGuidelines

Pipeline Progress, Updates Highlighted in This Week’s Industry Therapeutic Updates

Among the variety of Annual Meeting learning opportunities designed to arm attendees with the knowledge and tools to improve patient care are Industry Therapeutic Updates (ITUs). These popular sessions have been a mainstay of the Annual Meeting for many years, offering a unique chance for the Academy’s industry partners to highlight progress and updates within their respective pipelines and current therapies for patients with neurologic disease. Look for these opportunities throughout the week to engage with this important content:

Evening ITUs

Catch these programs Monday and Tuesday evenings at the Hyatt Regency and Embassy Suites hotels. Please check the mobile app for details.

Lunchtime ITUs

In addition to being able to attend evening ITUs, attendees can catch ITU sessions over the lunch hour, making it even easier to view multiple ITUs throughout the week. Look for lunchtime ITUs at the Convention Center in Bluebird 2 and 3, taking place Saturday through Wednesday from 11:45 a.m. to 12:45 p.m.

Livestreaming in the Online Platform

Select ITUs will be livestreamed in the online Annual Meeting platform during their regularly scheduled times only. They will not be available to revisit after the live session, so attendees are encouraged to connect with ITU hosting organizations for further details on any content they may have missed. Please note that it is optional for ITU hosting organizations to stream their content into the platform, so not all ITUs will be viewable in this manner.

How to Find Industry Therapeutic Updates

To learn more about the ITU lineup:

• Use the AAN Conferences mobile app to quickly search schedules; sessions are clearly delineated as being industry related and include the hosting company’s name

• Find the schedule in the Room Locator

• Connect with hosting companies prior to the meeting or on-site in their exhibit space

Innovative solutions in generalized myasthenia gravis (gMG), backed by a history of excellence in neurology

UCB is excited to introduce our recent advancements for adults living with gMG. Explore the possibilities at booth 1483

Kamilla, living with MG

Special Industry Presentations

Highlight Latest Technologies and Therapies at Exhibit Hall Presentation Stage, Booths

Be sure and stop by this year’s Emerging Neurologic Care Presentation Stage—located in Exhibit Hall B-E—Sunday through Wednesday for engaging short-form presentations centered on emerging technologies and therapies available to help improve overall patient care.

Emerging Neurologic Care Presentation Stage Schedule:

Takeda Pharmaceuticals Sunday, April 14 1:00 p.m.–1:20 p.m.

Hydro Heal Monday, April 15 12:30 p.m.–12:50 p.m.

Parexel Monday, April 15 1:00 p.m.–1:20 p.m.

Marinus Pharmaceuticals Tuesday, April 16 12:30 p.m.–12:50 p.m.

Praxis Precision Medicines Inc Tuesday, April 16 1:00 p.m.–1:20 p.m.

Grifols Wednesday, April 17 1:00 p.m.–1:20 p.m.

Additionally, the following companies will be offering exciting presentations in their respective booth spaces within the exhibit hall. Stop by these industry partner booths for a full list of their scheduled presentations:

• argenx, booth 1458

• IPSEN Biopharmaceuticals, booth 757

• Novartis Pharmaceuticals, booth 1475

• Sanofi, booth 1288

• UCB, Inc., booth 1483

Today’s Neuroscience in the Clinic Session to Address Emerging Autoantibodies in Neurologic Disease

Those looking for the latest information on autoantibodies will want to make their way to Bluebird 3E–H today between 2:30 p.m. and 4:30 p.m. for Neuroscience in the Clinic. Directors Claire Riley, MD, FAAN, and Marcelo Matiello, MD, FAAN, will be joined by expert faculty Josep O. Dalmau, MD, PhD, FAAN, and Sean J. Pittock, MD, and abstract presenters Mohamed Mostafa Rezk, MD, Beata Alicja Filipek, and Michael Gilligan, MBBS, to discuss the mechanisms of autoimmune responses targeting the nervous system. The presenters will also interpret current research findings related to emerging autoantibodies and the evolving landscape of autoimmune neurology. The session will conclude with a panel discussion along with opportunity for questions. Attendees may claim two CME credits.

Riley Matiello

Dalmau Pittock Rezk

Filipek Gilligan

AAN Announces Bold New Strategic Plan

With its first five-year strategic plan, the American Academy of Neurology looks to 2028 and beyond with a bold new mission statement and a renewed commitment to its vision to be indispensable to our members.

“The AAN’s long-standing vision—to be indispensable to our members—is staying the same,” said Lyell K. Jones, Jr., MD, FAAN, chair of the Strategic Planning Committee. “The AAN remains steadfast in our commitment to delivering value to our members at every turn in their careers. To reflect this commitment, the first part of our new mission makes it clear that we exist to enhance member career fulfillment. Our products, programs and services are developed with the goal of helping our members feel fulfilled at all stages of their neurology careers.”

The AAN is expanding its mission to “promote brain health for all.” As neurologists, neuroscience professionals, and students, the AAN’s more than 40,000 members around the world are uniquely positioned to simultaneously lead the treatment of neurologic disease and improvement of brain health.

AAN VISION

To be indispensable to our members

AAN MISSION

To enhance member career fulfillment and promote brain health for all

These values are another critical part of the new strategic plan:

AAN VALUES

• Community

• Leadership

• Well-being

• Diversity, Equity, and Inclusion

The new strategic plan includes a visionary roadmap that charts the AAN’s course in navigating the ever-evolving health care landscape. This roadmap includes the following four goals:

AAN GOALS

1. Grow a diverse neurology workforce

2. Strengthen neurologic practice

3. Promote neuroscience research

4. Improve neurologic health

Learn about how the AAN plans to achieve each of these goals at AAN.com/StrategicPlan. The objectives have been crafted with careful consideration, drawing upon the collective wisdom of members as the AAN outlines a bold vision for the future while continuing to deliver the world-class education, science, and advocacy you expect.

“Our future is bright, and I am inspired by our members and this roadmap to a future with improved brain health for all,” Jones said. “Our new strategic plan strengthens the AAN’s impact, enhances member engagement, and enables the AAN to lead the way in shaping the future of neurologic care.”

Jones

JOIN THE CONVERSATION #AANAM

Off to the American Academy of Neurology Annual Meeting! See you soon, @AANmember

Transforming Leaders Program is in Denver, on an elevator and ready for #AANAM!

When traveling, especially when traveling to Denver, it’s important to pack appropriately. Wear comfortable attire, stay hydrated, and bring something excellent to read #AANAM Nimish Mohile (he/him)

UMichNeurosciences

Like game shows, board games & neurology? Time to follow @zach_London at #AANAM! Dr. London will co-host “Dendritic Dare”, a neurology themed game show. He will also lead a session on building your own neuroscience board games — of which he has created 7 since 2015.

Aileen Antonio, MD, FAAN @aiee_antonio

#AANAM #BrainPAC

@UMneurosciences

Lyell Jones MD @LyellJ

@NimishMohile

Get the Inside Scoop on Denver—Straight from the Locals!

Who better than your fellow Denver-based AAN member colleagues to offer up an insider’s take on the must-knows to make your week in the Mile High City even more memorable.

Today’s Tip: Altitude Aptitude

“Some of my best advice for dealing with the altitude is to stay hydrated. Also, do things in moderation and don’t over-exert yourself once you get here. Eating regular meals also helps a lot.”

–Teri Schreiner, MD, MPH, FAAN

“Acclimating to the altitude is an issue for certain individuals. Here in Colorado, we are all fans of drinking a lot of water as the weather is very dry on top of being high, so keeping your hydration level optimal is going to be an advantage. Do not think you can hike immediately after arriving; allow yourself to breathe, sleep well, and recover.”

–Karen Dianne Orjuela, MD, FAAN

THE 2024 COMMITMENT TO CURES GALA IS TONIGHT!

We look forward to seeing many of you at the gala. Thank you for supporting neurologic research. It’s too late to register, but not too late to support this great cause. Make a donation now that counts towards this evening’s totals.

Stop by the American Brain Foundation booth at the end of the Grand Concourse to learn about available research grants, make a donation, or spin the prize wheel for exciting swag.

TO DONATE:

TEXT CURES24 to 56651

Tough on Duchenne. So it’s

easier to be him.

AGAMREE® Is a Novel Corticosteroid

• Developed to uncouple anti-inflammatory effects and certain corticosteroid-mediated adverse effects1,2

• Demonstrated statistically significant improvements in motor function3,4

• Established safety and tolerability profile in clinical studies3,4

SELECT IMPORTANT SAFETY INFORMATION

Warnings & Precautions

• Alterations in Endocrine Function: Monitor patients receiving AGAMREE for Cushing’s syndrome, hyperglycemia, and adrenal insufficiency after AGAMREE withdrawal. In addition, patients with hypopituitarism, primary adrenal insufficiency or congenital adrenal hyperplasia, altered thyroid function, or pheochromocytoma may be at increased risk for adverse endocrine events. Acute adrenal insufficiency can occur if AGAMREE is withdrawn abruptly, and could be fatal.

• Immunosuppression and Increased Risk of Infection: Use of corticosteroids, including AGAMREE, increases the risk of new infection, exacerbation of existing infections, dissemination, and reactivation or exacerbation of latent infection and may mask some signs of infection; these infections can be severe, and at times fatal.

• Alterations in Cardiovascular/Renal Function: Monitor for elevated blood pressure and monitor sodium and potassium levels in patients chronically treated with AGAMREE.

• Gastrointestinal Perforation: Use of corticosteroids increases the risk of gastrointestinal perforation in patients with certain gastrointestinal disorders, such as active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and non-specific ulcerative colitis. Signs and symptoms may be masked.

References

• Behavioral and Mood Disturbances: Potentially severe psychiatric adverse reactions may occur with systemic corticosteroids, including AGAMREE, and may include hypomanic or manic symptoms (eg, euphoria, insomnia, mood swings) during treatment and depressive episodes after discontinuation of treatment.

• Effects on Bones: Prolonged use of corticosteroids, such as AGAMREE, can lead to osteoporosis, which can predispose patients to vertebral and long bone fractures. Monitor bone mineral density in patients on longterm treatment with AGAMREE.

• Ophthalmic Effects: The use of corticosteroids, such as AGAMREE, may increase the risk of cataracts, ocular infections, and glaucoma. Monitor intraocular pressure if treatment with AGAMREE is continued for more than 6 weeks.

• Vaccination: Do not administer live-attenuated or live vaccines to patients receiving AGAMREE. Administer live-attenuated or live vaccines at least 4 to 6 weeks prior to starting AGAMREE. Please see Brief Summary of full Prescribing Information on the next page.

1. Liu X, et al. Proc Natl Acad Sci USA. 2020;117(39):24285-24293. 2. Heier CR, et al. EMBO Mol Med. 2013;5(10):1569-1585. 3. AGAMREE (vamorolone) Oral Suspension [prescribing information]. Catalyst Pharmaceuticals, Inc.; 2023. 4. Guglieri M, et al. JAMA Neurol. 2022;79(10):1005-1014.

AGAMREE® (vamorolone) oral suspension

BRIEF SUMMARY – See Full Prescribing Information at AGAMREEhcp.com

Initial U.S. Approval: 2023

INDICATIONS AND USAGE

AGAMREE is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.

DOSAGE AND ADMINISTRATION

Dosing Information

The recommended dosage of AGAMREE is 6 mg/kg taken orally once daily preferably with a meal, up to a maximum daily dosage of 300 mg for patients weighing more than 50 kg.

Some patients may respond to a dose of 2 mg/kg daily. Doses may be titrated down to 2 mg/kg/day as needed, based on individual tolerability.

Discontinuation

Dosage of AGAMREE must be decreased gradually if the drug has been administered for more than one week.

CONTRAINDICATIONS

AGAMREE is contraindicated in patients with known hypersensitivity to vamorolone or to any of the inactive ingredients of AGAMREE. Instances of hypersensitivity, including anaphylaxis, have occurred in patients receiving corticosteroid therapy.

WARNINGS AND PRECAUTIONS

Alterations in Endocrine Function

Corticosteroids, such as AGAMREE, can cause serious and life-threatening alterations in endocrine function, especially with chronic use. Monitor patients receiving AGAMREE for Cushing’s syndrome, hyperglycemia, and adrenal insufficiency after AGAMREE withdrawal. In addition, patients with hypopituitarism, primary adrenal insufficiency or congenital adrenal hyperplasia, altered thyroid function, or pheochromocytoma may be at increased risk for adverse endocrine events.

Acute adrenal insufficiency can occur if AGAMREE is withdrawn abruptly, and could be fatal. The risk of adrenal insufficiency is reduced by gradually tapering the dose when withdrawing treatment. For patients already taking corticosteroids during times of stress, the dosage may need to be increased.

Immunosuppression and Increased Risk of Infection

Corticosteroids, including AGAMREE, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can reduce resistance to new infections, exacerbate existing infections, increase the risk of disseminated infections, increase the risk of reactivation or exacerbation of latent infections, and mask some signs of infection. Corticosteroid-associated infections can be severe, and at times fatal infections can occur. The rate of infectious complications increases with increasing corticosteroid dosages.

Corticosteroids cause a dose-dependent increase in lymphocyte and neutrophil counts. Monitor for the development of infection and consider AGAMREE withdrawal or dosage reduction as needed.

Varicella Zoster and Measles Viral Infections Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids. In corticosteroid-treated patients who have not had these diseases or are non-immune, particular care should be taken to avoid exposure to varicella and measles.

• If an AGAMREE-treated patient is exposed to varicella, prophylaxis with varicella zoster immunoglobulin may be indicated. If varicella develops, treatment with antiviral agents may be considered.

• If an AGAMREE-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated.

Hepatitis B Virus Reactivation

Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids. Reactivation can also occur in corticosteroid-treated patients who appear to have resolved hepatitis B infection.

Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with AGAMREE. For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy.

Fungal Infections

Corticosteroids may exacerbate systemic fungal infections; therefore, avoid AGAMREE use in the

presence of such infections. For patients on chronic AGAMREE therapy who develop systemic fungal infections, AGAMREE withdrawal or dosage reduction is recommended.

Amebiasis

Corticosteroids may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating AGAMREE in any patient who has spent time in the tropics or any patient with unexplained diarrhea.

Strongyloides Infestation

Corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia. For patients on corticosteroids who develop known or suspected Strongyloides (threadworm) infestation, withdrawal of corticosteroids or reduction of the dose of corticosteroids is recommended.

Alterations in Cardiovascular/Renal Function

Corticosteroids, including AGAMREE, can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium and calcium.

Monitor blood pressure and assess for signs and symptoms of volume overload. Monitor serum potassium levels.

AGAMREE should be used with caution in patients with congestive heart failure, hypertension, or renal insufficiency. Literature reports suggest an association between use of corticosteroids and left free wall rupture after a recent myocardial infarction; therefore, therapy with AGAMREE should be used with great caution in these patients.

Gastrointestinal Perforation

There is an increased risk of gastrointestinal perforation with the use of corticosteroids in patients with certain gastrointestinal disorders, such as active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and non-specific ulcerative colitis. Signs of gastrointestinal perforation, such as peritoneal irritation, may be masked in patients receiving corticosteroids.

Avoid AGAMREE if there is a probability of impending perforation, abscess, or other pyogenic infections; diverticulitis; fresh intestinal anastomoses; or active or latent peptic ulcer.

Behavioral and Mood Disturbances

Potentially severe psychiatric adverse reactions may occur with systemic corticosteroids, including AGAMREE. Symptoms typically emerge within a few days or weeks of starting treatment and may be dose-related. These reactions may improve after either dose reduction or withdrawal, although pharmacologic treatment may be necessary.

Inform patients or caregivers of the potential for behavioral and mood changes and encourage them to seek medical attention if psychiatric symptoms develop, especially if depressed mood or suicidal ideation is suspected.

Effects on Bones

Decreased Bone Mineral Density

Corticosteroids, such as AGAMREE, decrease bone formation and increase bone resorption both through their effect on calcium regulation (i.e., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of bone loss at any age. Bone loss can predispose patients to vertebral and long bone fractures.

Consider a patient’s risk of osteoporosis before initiating corticosteroid therapy. Monitor bone mineral density in patients on long-term treatment with AGAMREE.

Avascular Necrosis

Corticosteroids may cause avascular necrosis.

Ophthalmic Effects

The use of corticosteroids, such as AGAMREE, may produce posterior subcapsular cataracts. Corticosteroids may also cause glaucoma with possible damage to the optic nerves, and may increase the risk of secondary ocular infections caused by bacteria, fungi, or viruses.

Corticosteroids are not recommended for patients with active ocular herpes simplex. Intraocular pressure may become elevated in some patients taking corticosteroids. If treatment with AGAMREE is continued for more than 6 weeks, monitor intraocular pressure.

Immunizations

Administer all immunizations according to immunization guidelines prior to starting AGAMREE. Administer liveattenuated or live vaccines at least 4 to 6 weeks prior to starting AGAMREE. Patients on AGAMREE may receive concurrent vaccinations, except for live-attenuated or live vaccines.

Effects on Growth and Development

Long-term use of corticosteroids, including AGAMREE, can have negative effects on growth and development in children.

Myopathy

Patients receiving corticosteroids and concomitant therapy with neuromuscular blocking agents (e.g., pancuronium) or patients with disorders of neuromuscular transmission (e.g., myasthenia gravis) may be at increased risk of developing acute myopathy. This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.

Kaposi’s Sarcoma

Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of treatment may result in clinical improvement of Kaposi’s sarcoma.

Thromboembolic Events

Observational studies have shown an increased risk of thromboembolism (including venous thromboembolism) particularly with higher cumulative doses of corticosteroids. It is unclear if risk differs by daily dose or duration of use. Use AGAMREE with caution in patients who have or may be predisposed to thromboembolic disorders.

Anaphylaxis

Rare instances of anaphylaxis have occurred in patients receiving corticosteroid therapy.

ADVERSE REACTIONS

The following serious adverse reactions are discussed in more detail in other sections:

• Alterations in Endocrine Function

• Immunosuppression and Increased Risk of Infection

• Alterations in Cardiovascular/Renal Function

• Gastrointestinal Perforation

• Behavioral and Mood Disturbances

• Effects on Bones

• Ophthalmic Effects

• Immunizations

• Effects on Growth and Development

• Myopathy

• Kaposi’s Sarcoma

• Thromboembolic Events

• Anaphylaxis

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Common Adverse Reactions in Clinical Studies

Table 1 lists the adverse reactions that occurred in ≥5% of the patients treated with AGAMREE 6 mg/kg/ day (N=28) or AGAMREE 2 mg/kg/day (N=30) and that occurred more frequently than in the patients who received placebo (N=29) in Study 1, which was 24 weeks and included patients with DMD between the ages of 4 and 7 years.

Table 1: Adverse Reactions in Patients with DMD that Occurred in ≥5% of Patients Treated with AGAMREE and More Frequently than in Patients Who Received Placebo During 24 Weeks (Study 1)

USE IN SPECIFIC POPULATIONS

Pregnancy

Risk Summary

AGAMREE is indicated for use for the treatment of DMD, which is a disease of young male patients. However, corticosteroids in general should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. There are no data on the use of AGAMREE during pregnancy.

Animal reproduction studies have not been conducted with AGAMREE.

Lactation

Risk Summary

There are no data on the presence of vamorolone in human milk or the effects on milk production.

AGAMREE is indicated for use for the treatment of DMD, which is a disease of young male patients. However, systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need and any potential adverse effects on the breastfed infant.

Pediatric Use

The safety and effectiveness of AGAMREE for the treatment of DMD have been established in patients 2 years of age and older. Use of AGAMREE in pediatric patients is supported by a multicenter, randomized, double-blind, placebo- and active-controlled study in 121 males 4 to less than 7 years of age. Use of AGAMREE in patients 2 years to less than 4 years of age and 7 to less than 18 years of age is supported by findings of efficacy and safety in patients 4 to less than 7 years of age with DMD, and by pharmacokinetic and safety data from patients 2 to 4 years of age and 7 to less than 18 years of age.

The safety and effectiveness in pediatric patients below the age of 2 years have not been established.

Geriatric Use

DMD is largely a disease of children and young adults; therefore, there is no geriatric experience with AGAMREE.

Hepatic Impairment

Moderate hepatic impairment increases vamorolone exposure. Reduce the AGAMREE dosage in patients with mild to moderate hepatic impairment. There is no clinical experience with AGAMREE in patients with severe hepatic impairment, and a dosing recommendation cannot be provided for patients with severe hepatic impairment.

CLINICAL PHARMACOLOGY

Mechanism of Action

Vamorolone is a corticosteroid that acts through the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects. The precise mechanism by which vamorolone exerts its effect in patients with DMD is unknown.

Pharmacodynamics

Vamorolone produced a dose-dependent decrease in morning cortisol levels in the clinical studies. Treatment with corticosteroids is associated with a suppression of endogenous cortisol concentrations and an impairment of the hypothalamus-pituitary-adrenal (HPA) axis function. A dose-dependent increase in leukocyte counts and lymphocyte counts was observed in clinical studies with vamorolone.

Cardiac Electrophysiology

Vamorolone does not cause a mean increase in the QTc interval >20 milliseconds (ms) at 1.6 times the approved recommended dose.

See full Prescribing Information available at AGAMREEhcp.com.

1Includes the following adverse reactions that occurred more frequently in the AGAMREE group than in placebo: abnormal behavior, aggression, agitation, anxiety, irritability, mood altered, sleep disorder, and stereotypy.

In a separate open-label safety study of pediatric patients aged 2 to less than 4 years (n=16) and pediatric patients aged 7 to less than 18 years (n=16) with DMD, adverse reactions were similar to those seen in the Study 1 pediatric patients.

DRUG INTERACTIONS

Effect of Other Drugs on Vamorolone Co-administration of AGAMREE with itraconazole, a strong CYP3A4 inhibitor, increases vamorolone exposure. Reduce the dosage of AGAMREE in patients when strong CYP3A4 inhibitors are used concomitantly. No dosage adjustments are required when AGAMREE is concomitantly administered with moderate or weak CYP3A4 inhibitors.

Neurology Education Room Provides Unique Space for Teaching, Mentorship, Networking, Community

Elevate education and the educator community this week by stopping by the AAN's Neurology Education Room located in Mile High 1BCD. This dynamic space offered in collaboration with the Association of University Professors of Neurology (AUPN) is designed to foster excellence in neurology education through a blend of teaching, mentorship, and networking opportunities. All are welcome to join this vibrant community of educators empowering other educators to shape the future of neurology.

Schedule:

Saturday, April 13

Neurology Education: Clerkship and Program Directors Conference: DEI in Undergraduate and Graduate Medical Education

Director: Rebecca E. Matthews, MD 7:00 a.m.–11:30 a.m.

Neurology Education: Roundtable Lunch: What Is the Best (and Worst) Narrative Comment You Have Written or Received?

Facilitators: Katherine Fu, MD, and Adam Quick, MD 12:00 p.m.–12:45 p.m.

Neurology Education: Welcome to the Neurology Education Room

Directors: Tracey A. Milligan, MD, FAAN, and Roy E. Strowd, III, MD, FAAN 1:30 p.m.–2:30 p.m.

Neurology Education: Research Blitz

Director: Jeremy Moeller, MD, FAAN 3:00 p.m.–4:30 p.m.

Sunday, April 14

Neurology Education: Hot Topics in Clinical Practice: Advances in Neurology Education

Director: David Wolf, MD, PhD 7:00 a.m.–9:00 a.m.

Neurology Education: Roundtable Lunch: What Online Learning Tools Are You Using to Learn and Teach?

Facilitators: Jessica B. Kraker, MD, FAAN, and Felicia Gliksman, DO, FAAN 12:00 p.m.–12:45 p.m.

Neurology Education: Clerkship and Program Directors Skills Building Work Group

Director: Neil Masangkay, MD 1:00 p.m.–4:00 p.m.

Neurology Education: Educator Mentoring Session

Directors: Sarah Christine Parauda, MD, and Chaitanya Medicherla, MD 4:30 p.m.–5:30 p.m.

Monday, April 15

Neurology Education: A. B. Baker Award for Lifetime Achievement in Neurologic Education

Keynote Address: Joel C. Morgenlander, MD, FAAN 11:00 a.m.–11:45 a.m.

Neurology Education: Roundtable Lunch Potpourri: 10 Tables and 10 Topics

Facilitators: Multiple 12:00 p.m.–12:45 p.m.

Neurology Education: Practical Introduction to Foundational Educational Principles and Methodology

Director: Roy E. Strowd, III, MD, FAAN

1:30 p.m.–3:00 p.m.

Neurology Education: (Reverse) Shark Tank

Director: Steven Galetta, MD, FAAN 3:30 p.m.–5:30 p.m.

Tuesday, April 16

Neurology Education: Faculty Development: Enhancing Your Role in Student and Resident Training

Mark Milstein, MD, FAAN 7:00 a.m.–9:00 a.m.

Neurology Education: Roundtable Lunch Potpourri: 10 Tables and 10 Topics

Facilitators: Multiple 12:00 p.m.–12:45 p.m.

Neurology Education: Mastering the Art of Simulation Education

Director: Nicholas Allen Morris, MD, FAAN 1:30 p.m.–3:00 p.m.

Neurology Education: Keynote: Artificial Intelligence in Medical and Neurologic Education

Director: Martin Pusic, MD 3:30 p.m.–4:30 p.m.

Neurology Education: A. B. Baker Showcase

Director: Dara V. Albert, DO, FAAN 4:45 p.m.–5:45 p.m.

Wednesday, April 17

Neurology Education: Addressing Unprofessional Behaviors

Director: Asif Doja, MD, FAAN 7:00 a.m.–9:00 a.m.

Neurology Education: Roundtable Lunch Potpourri: 10 Tables and 10 Topics

Facilitators: Multiple 12:00 p.m.–12:45 p.m.

Neurology Education: Teach Around the Circle

Director: Jessica Helena Goldstein, MD 1:30 p.m.–3:00 p.m.

Neurology Education: Charcot’d Breakers: Creating Puzzles to Educate and Engage

Director: Zachary N. London, MD, FAAN 3:30 p.m.–5:30 p.m.

Thursday, April 18

Neurology Education: Negotiating with Your Department and Institution as an Educator

Directors: David M. Greer, MD, FAAN, Tracey A. Milligan, MD, FAAN, and Thabele M. Leslie-Mazwi, MD 7:00 a.m.–9:00 a.m.

Hot Topics

Brain Health Across the Lifespan Is Focus of Today’s Hot Topics Plenary

Make your way to the Bellco Theatre between 4:45 p.m. and 5:45 p.m. this evening to hear three outstanding speakers provide summaries of their recent cutting-edge translational research findings related to brain health across the lifespan.

The session will be moderated by:

Riley Bove, MD, FAAN Member, Science Committee

Progression, Regeneration, and Physical Activity in Pediatric MS

E. Ann Yeh, MA, MD, FRCPC The Hospital for Sick Children, Toronto, ON, Canada

Powered by Numbers: Leveraging Epidemiological Data to Accelerate Research into Action to Improve Outcomes in Traumatic Brain Injury

Andrea L. C. Schneider, MD, PhD University of Pennsylvania, Philadelphia, PA

Health Disparities and Their Effect on Brain Health

Altaf Saadi, MD Massachusetts General Hospital, Boston, MA

Share your thoughts about the Hot Topics Plenary Session on social media using #AANAM.

Today’s Hub Highlights

Step outside the traditional classroom and into the world of out-of-the-box learning with eight hub areas. Each hub offers unique educational and networking opportunities and creative programs that leave participants with take-home skills and resources for their patients, practices, and careers.

Here are today’s highlights:

Academic Hub

Mile High Lobby

Conversation Corner: The PUMP Law: Practical Applications for Lactating Neurology Health Care Providers

1:30 p.m.–2:00 p.m.

The 2022 PUMP Act (Providing Urgent Maternal Protections (PUMP) for Nursing Mothers) expanded requirements for employers to provide a reasonable break time for an employee to express breast milk and a private place to pump at work. Deborah Hall, MD, PhD, FAAN, Deborah Olmstead Setter, MD, PhD, and Nicole Ullrich, MD, PhD, MMSci, FAAN, will discuss practical applications for supporting lactating neurology health care providers. From advocating for protected lactation break time to ensuring adequate facilities and considering productivity adjustments, faculty will address the needs of both parents and academic leadership. Discover actionable recommendations and insights to create a more inclusive and supportive environment for neurologists navigating the intersection of parenthood and professional life.

Conversation Corner: Corporate Pressures in Academic Medicine

4:30 p.m.–5:00 p.m.

Join Steven L. Lewis, MD, FAAN, for a conversation on how to navigate corporate pressures in academic medicine.

HeadTalks

Lobby B

Benefits and Perils of Skiing: From Mental Wellbeing and Longevity to Ski Boot Compression Syndrome

2:15 p.m.–3:00 p.m.

Maciej M. Mrugala, MD, PhD, MPH, FAAN, and a panel of experts will discuss the mental and physical benefits of skiing, as well as some of the more common neurologic symptoms skiers may experience.

Neurology on the Screen

3:45 p.m.–4:30 p.m.

In the first of many light-hearted game show-style offerings presented at the HeadTalks stage, you can test your knowledge of how neurology topics are presented in popular movies and TV shows. Watch out for tomorrow’s Neuro-Jeopardy and Dendritic Dare games, as well as Neurology Pictionary, Neuro Olympics, and more throughout the meeting.

Hall Setter Ullrich

Lewis

Mrugala

SATURDAY, APRIL 13

Leadership University

Mile High Lobby

The Chief Files: Difficult Discussions with Physicians

3:30 p.m.–4:30 p.m.

Izzo

Learn from Anthony Izzo, DO, FAAN, about the leadership skills necessary to have difficult conversations with other practitioners across disciplines and the wider health care system.

Take the Implicit Bias Test

Saturday, April 13–Wednesday, April 17, 8:30 a.m.–4:30 p.m.

Stop by and take the implicit bias test from Project Implicit, a nonprofit international research network that explores implicit social cognition, uncovering hidden biases to enhance awareness, promote diversity, improve decision-making, and align practices with personal and organizational values.

Practice and Policy Hub

Lobby F

Healing Doubt: Confronting and Overcoming Medical Gaslighting

12:00 p.m.–12:30 p.m.

Come explore what is sure to be a compelling and demystifying conversation on medical gaslighting. Michele Longo, MD, FAAN, and Jessica B. Kraker, MD, FAAN, will dissect the mechanisms behind this term and examine the biases and challenges faced by both patients and health care clinicians.

Operationalizing Advanced Drug Services from Screening to Infusion

1:00 p.m.–2:00 p.m.

Katherine Coerver, MD, PhD, FAAN, Lidia Maria Veras Rocha Moura, MD, PhD, MPH, FAAN, Amy Rene Knighton, and Marcelo Matiello, MD, FAAN, will review challenges with anti-amyloid therapy from screening to infusion. They will cover collaborative multi-disciplinary team models and value-based care approaches to optimize cognitive screening and intervention, emerging tools for comprehensive screening, and addressing disparities in aging care.

Longo Kraker

Knighton

Veras Rocha Moura Coerver Matiello

Today’s Hub Highlights

Research Hub

Exhibit Hall D Lobby

SUNDAY

Don’t Miss Tomorrow’s Coffee Connect for Women Researchers

8:00 a.m.–9:00 a.m. Sunday

Women in research can start their morning off with coffee, making connections with other researchers, and learning about new research resources.

Trainee Hub

Lobby D

Consortium of Neurology Education Coordinators Business Meeting

12:30 p.m.–1:30 p.m.

All education coordinators are invited to network, learn about programming designed for them in the Trainee Hub, and meet recipients of the 2024 Neurology Education Coordinator Recognition Award.

How to Prepare for Interviews (for Residency and Everything Else)

12:00 p.m.–1:30 p.m.

Learn how the residency interview process works, including a preview of the upcoming cycle. Participants will practice crafting an impactful response to typical interview questions and prepare an elevator pitch for the “tell me about yourself” question. There will be time for feedback on attendee answers to sample questions.

Residents and Fellows Meet and Greet

2:00 p.m.–3:00 p.m.

All residents and fellows attending the Annual Meeting are encouraged to attend this meet and greet to hear about resources and programs of interest from Logan D. Schneider, MD, and to meet and network with peers.

Wellness Hub

Exhibit Hall D Lobby

NeuroBeats: An Annual Meeting Dance Break

12:00 p.m.–12:30 p.m.

Join Ashley Mary Paul, MD, for a dance fitness session where rhythm meets wellness! No dance experience required. Explore the therapeutic power of movement and boost your brain health while having a blast.

Brazilian Jiu-jitsu

3:30 p.m.–4:15 p.m.

Rodolfo Savica, MD, PhD, FAAN, will lead this introduction to the practice and health benefits of Brazilian jiu-jitsu—open to all experience levels.

Schneider

Savica

Seamlessly Experience the Annual Meeting Through the Mobile App and Online Platform

Access this week’s robust offerings in whatever way works best for you—in person or online! Be sure to download the AAN Conferences mobile app in the App Store or Google Play for seamless synchronization between the two to get the biggest benefit from your meeting experience. You can:

• Access session recordings on AAN Rewind

• Access program materials* and evaluations to claim CME

• Livestream select sessions

• Switch between the app and the online platform with synced agenda, messaging, and more

• View maps for easy navigation throughout the Colorado Convention Center

• Turn on push notifications for helpful conference reminders and tips

Need support for the online platform or mobile app?

Visit Meeting Information near the Big Blue Bear.

* Availability of program materials is at the discretion of the specific speaker. Not all sessions will have materials.

Today’s Society Spotlight Focuses on Hot Topics in Neuropsychiatry

The AAN is partnering with the American Neuropsychiatric Association for today’s Society Spotlight session (formerly Invited Science) from 12:00 p.m. to 2:00 p.m. in room 601. Participants will hear updates on the cutting-edge science of hot topics in neuropsychiatry from authors giving encore presentations of top abstracts presented at American Neuropsychiatric Association meetings. Select abstracts will emphasize basic, clinical, and translational science as they evolve toward a more complete understanding of neuropsychiatry with the overall goal of developing more effective prevention and treatment.

Abstracts and authors include:

12:00 p.m.–12:20 p.m.

Evaluation of Memory Remediation in Traumatic Brain Injury with Donepezil (the MEMRI-TBI-D Study): A Randomized Controlled Trial

David B. Arciniegas, MD

12:20 p.m.–12:40 p.m.

Cognitive Profiles and Salience Network Connectivity: Associations with Treatment Response in Posttraumatic Stress Disorder

Kaloyan Tanev, MD

12:40 p.m.–1:00 p.m.

A Biopsychological Approach to the Stress-diathesis Model in Functional Neurological Disorders

Selma Aybek, MD, FAAN

1:00 p.m.–1:20 p.m.

Network Localization of Spontaneous Confabulation

James R. Bateman, III, MD

1:20 p.m.–1:40 p.m.

Mild Behavioral Impairment (MBI) and the Risk of Incident Dementia in a Population-based Setting

Yonas E. Geda, MD

1:40 p.m.–2:00 p.m.

Large Scale Lesion Symptom Mapping of Depression Identifies Distinct Brain Regions for Risk and Resilience

Nicholas Trapp

Celebrate These 2024 AAN Education Award Recipients

The AAN recognizes the 2024 AAN education award recipients and their contributions to the art and science of neurology.

A.B. BAKER AWARD FOR LIFETIME ACHIEVEMENT IN NEUROLOGIC EDUCATION

Funded by an endowment created by matching funds from the A.B. Baker Family Trust and Novartis Pharmaceuticals.

Joel C. Morgenlander, MD, FAAN

Duke University, Durham, NC

A. B. BAKER TEACHER RECOGNITION AWARD

Lealani Mae Acosta, MD, FAAN

Vanderbilt University, Nashville, TN

John C. Adair, MD

University of New Mexico, Albuquerque, NM

Alhamza Al-Bayati, MD

University of Pittsburgh, Pittsburgh, PA

Ana C. Albuja Ponce

Brown Medical School, Providence, RI

Ashhar Ali, DO, FAAN

Henry Ford Health, Bloomfield Twp, MI

Tarek Emran Ali, MBBS

University of Kentucky, Lexington, KY

Yasir Al-Khalili, MD, MSED, FAAN

Virginia Commonwealth University, Richmond, VA

Baxter Allen, MD

Weill Cornell, New York, NY

Graham Atkin, PhD

Michigan State University, East Lansing, MI

Ekaterina Bakradze, MD University of Alabama, Birmingham, AL

Benjamin Barnes, MD

Augusta University, Augusta, GA

Christopher R. Barton, MD

University of Louisville, Louisville, KY

Maysaa Merhi Basha, MD

Wayne State University, Detroit, MI

Bassam A. Bassam, MD, FAAN

University of South Alabama, Mobile, AL

Aaron M. Carlson, MD

University of Colorado – Denver, Denver, CO

Rameshwar Nath Chaurasia, MBBS, MD, DM, FRCP, MAMS

Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India

Suzanne C. Crandall, DO

Charleston Area Medical Center, Charleston, WV

Alok Dabi, MD

University of Texas Medical Branch, Galveston, TX

Long F. Davalos Loo, MD

University of Cincinnati, Cincinnati, OH

Bertha C. Ekeh, MD

University of Uyo Teaching Hospital

Uyo, Akwa Ibom, Nigeria

Jessica Feldman, MD

Penn Medicine, Sellersville, PA

Anteneh Mekonnen Feyissa, MD, MSc, FAAN

Mayo Clinic – Jacksonville, Jacksonville, FL

Erin Furr-Stimming, MD, FAAN

McGovern Medical School, UTHealth, Houston, TX

Daniel Gonzalez, MD

Barrow Neurological Institute, Phoenix, AZ

Carolina Garcia, DO

Emory University, Atlanta, GA

Jennifer L. Griffith, MD

Washington University, St. Louis, MO

James Grogan, MD

Pennsylvania State University, State College, PA

Sheffali Gulati, MD, FAMS, FIAP, FIMS

All India Institute of Medical Sciences, New Delhi, India

Khalid Hanafy, MD, PhD

Cooper Neurologic Institute, Cherry Hill, NJ

Antonio Hernanado Iglesias, MD

Loyola University, Chicago, IL

Ryan David Jacobson, MD

Rush University, Chicago, IL

Peter Jin, MD

University of Maryland, College Park, MD

Morgan Christina Jordan, DO

Uniformed Services University of Health Sciences, Bethesda, MD

Tamara B. Kaplan, MD

Brigham and Women's, Boston, MA

Sukriye Damla Kara, MD

University of Mississippi, Jackson, MS

Adrienne M. Keener, MD

UCLA, Los Angeles, CA

Nishanth Kodumuri, MD

University of South Carolina, Columbia, SC

Scheherazade Le, MD

Stanford University, Stanford, CA

Hongyan Li, MD, PhD, FAAN

University of Toledo, Toledo, OH

Jason H. Margolesky, MD

University of Miami, Miami, FL

Ethan Isaac Meltzer, MD

University of Texas – Austin, Austin, TX

Jose Antonio Montes-Rivera, MD

University of Connecticut, Mansfield, CT

Andrew James Natonson, MD

Oregon Health and Science University, Portland, OR

Scott Douglas Newsome, DO, FAAN

Johns Hopkins, Baltimore, MD

Scott I. Otallah, MD

Wake Forest, Winston-Salem, NC

Ashok Reddy Polu, MD

The NeuroMedical Center Clinic, Baton Rouge, LA

Varun Chandra Reddy Pulakanti, MD

Geisinger, Danville, PA

Reshma Narula, MD

Yale Medicine, New Haven, CT

Matthew Roberts, MD

University of Texas Health Science CenterSan Antonio, San Antonio, TX

Hannah Roeder, MPH

University of Iowa, Iowa City, IA

Sean C. Rose, MD, FAAN

Nationwide Children's Hospital, Toledo, OH

Helene Rubeiz, MD

University of Chicago, Chicago, IL

Sami Saba, MD

Northwell Health, New York, NY

Stefano Sandrone, PhD

Imperial College London, London, England

Courtney Seebadri-White, MD

Thomas Jefferson University, Philadelphia, PA

Rajesh Shankar Iyer, MD, DM

Kovai Medical Center and Hospital, Tamil Nadu, India

Zubeda B. Sheikh, MD

West Virginia University, Morgantown, WV

Kurt Michael Sieloff, MD

University of Michigan, Ann Arbor, MI

Alexis N. Simpkins, MD, PhD, MSCR, FAAN

Cedars-Sinai Medical Center, Los Angeles, CA

Thomas Thesen, PhD

Geisel School of Medicine, Hanover, NH

Michel Toledano, MD

Mayo Clinic – Rochester, Rochester, MN

Jose L. Torres, MD

NYU – Langone, New York, NY

Anh-Thu Ngo Vu, MD, MS

Providence Health & Services, Renton, WA

Neal J. Weisbrod, MD

University of Florida, Gainesville, FL

Kathryn Leigh Idol Xixis, MD

University of Virginia, Charlottesville, VA

CLERKSHIP DIRECTOR INNOVATION AWARD

Amit Kandel, MD

University at Buffalo SUNY, Buffalo, NY

CLERKSHIP DIRECTOR TEACHING AWARD

Matthew Swan, MD

Icahn School of Medicine at Mount Sinai, New York, NY

CONSORTIUM OF NEUROLOGY RESIDENTS AND FELLOWS ESSAY CONTEST

Nara Michaelson, MD

Baylor Scott & White, Dallas, TX

DIRECTOR MENTORSHIP LEADERSHIP PROGRAM

Supported in part by LivaNova.

Margaret Adler, MD

Harbor UCLA Medical Center, Torrance, CA

Jennifer M. Bain, MD, PhD

Columbia University, New York, NY

Meeryo Choe, MD, FAAN

UCLA Mattel Children's Hospital, Los Angeles, CA

Kristen Fisher, DO

Baylor College of Medicine, Houston, TX

Tiffani Stroup Franada, DO

OSF Healthcare Illinois Neurological Institute, Peoria, IL

Katherine Fu, MD

UCLA Medical Center, Los Angeles, CA

Elysia James, MD

University of Toledo, Toledo, OH

Balaji Krishnaiah, MD, FAAN

University of Tennessee Health Sciences Center, Memphis, TN

Zabeen Kaizar Mahuwala, MD, FAAN

University of Kentucky, Lexington, KY

Alexandra Kvernland, MD

NYU Department of Neurology, New York, NY

Jeremy Moeller, MD, FAAN

Yale University, New Haven, CT

Aaron Lane Nelson, MD, FAAN

NYU Langone Health, New York, NY

Douglas Ney, MD, FAAN

University of Colorado School of Medicine, Aurora, CO

Ligia V. Onofrei, MD

University of Utah, Salt Lake City, UT

Michael L. Palm, MD, FAAN

UT Health San Antonio, San Antonio, TX

Jeffrey B. Ratliff, MD, FAAN

Thomas Jefferson University, Philadelphia, PA

Justin A. Sattin, MD

University of Wisconsin, Madison, WI

Buse Sengul, MD

Memorial Healthcare System, Hollywood, FL

Elizabeth T. Troy, MD

University of Colorado, Aurora, CO

Robin Ulep, MD

Icahn School of Medicine at Mount Sinai, New York, NY

Stephen A. VanHaerents, MD, FAAN

Northwestern University, Chicago, IL

Starla Wise, DO

University of Cincinnati, Cincinnati, OH

Kathryn Leigh Idol Xixis, MD

University of Virginia, Charlottesville, VA

ENHANCED RESIDENT LEADERSHIP PROGRAM

Supported in part by Alexion Pharmaceuticals and LivaNova.

Claudia Gambrah-Lyles, MD

Children's Hospital of Philadelphia, Philadelphia, PA

Franziska Hoche, MD

Massachusetts General Hospital, Boston, MA

Christine Gummerson, MD

Yale New Haven Hospital, New Haven, CT

Ruben Jauregui, MD

NYU – Langone, New York, NY

Neeharika Krothapalli, DO

University of Connecticut, Farmington, CT

Michael D. Liu, MD

Mayo Clinic, Rochester, MN

Meagan Newell, MD

Baylor College of Medicine, Houston, TX

Praveen Ramani, MBBS

University of Arkansas / Arkansas Children's Hospital, Little Rock, AR

Deborah Kathleen Rose, MD

Duke University, Durham, NC

Angela C. Russell, MD

University of Calgary, Calgary, Canada

Christine Shrock, MS

Boston Children's Hospital, Brookline, MA

Isha Snehal, MBBS

University of Nebraska, Omaha, NE

Maria Sokola, MD

Cleveland Clinic Foundation, Cleveland, OH

Megan E. Super, MD

Thomas Jefferson University, Philadelphia, PA

Adam Wadina, MD

Loyola University, Maywood, IL

FRANK A. RUBINO AWARD FOR EXCELLENCE IN CLINICAL NEUROLOGY

TEACHING

Funded by the Mayo Clinic Frank A. Rubino, MD Development Fund.

Vanja C. Douglas, MD

University of California, San Francisco, San Francisco, CA

NEUROSCIENCE COURSE DIRECTOR EXCELLENCE AWARD

Jose L. Torres, MD

NYU – Langone, New York, NY

RESIDENCY EDUCATION COORDINATOR

RECOGNITION AWARD

Caroline E. Martin, MA

University of Iowa, Iowa City, IA

Nadia Tilden-Dassler

Westchester Medical Center, Valhalla, NY

FELLOWSHIP EDUCATION COORDINATOR

RECOGNITION AWARD

Juliana Adepipe

University of Pennsylvania, Philadelphia, PA

Nina Galanti

University of Michigan, Ann Arbor, MI

CLERKSHIP EDUCATION COORDINATOR

RECOGNITION AWARD

Courtney Lewis

University of Maryland, Baltimore, MD

RESIDENCY-FELLOWSHIP PROGRAM DIRECTOR

RECOGNITION AWARD

Daniel R. Gold, DO

Johns Hopkins Medicine, Baltimore, MD

Christopher Hess, MD

University of Florida, Gainesville, FL

Robert W. Neel, MD

University of Cincinnati Hospital, Cincinnati, OH

Rana R. Said, MD, FAAN

UT Southwestern, Dallas, TX

RESIDENT & FELLOW WRITING AWARD

Sponsored by the Neurology Resident & Fellow Section.

Ana M. Cabal Herrera, MD

Nationwide Children’s Hospital, Columbus, OH

Setty Magaña, MD, PhD

Nationwide Children’s Hospital, Columbus, OH

Quinton J. Mandle, MD

Nationwide Children’s Hospital, Columbus, OH

Alex Sunshine, MD, PhD

Nationwide Children's Hospital, Columbus, OH

Hersh Varma, MD

Nationwide Children’s Hospita, Columbus, OH

Bianca Zapanta, DO

Nationwide Children’s Hospital, Columbus, OH

Focus Your Annual Meeting Schedule with Targeted Interests

Looking for some help planning your week? Check out our pre-selected targeted interest lineups of focused topic-based programming, ranging from educational courses and scientific presentations to networking opportunities and hub talks.

Targeted interests include:

Advanced Practice Providers

Includes programming specifically geared to advanced practice providers.

Artificial Intelligence

Highlights talks and presentations focusing on the timely topic of artificial intelligence.

Brain Health

Features talks and presentations related to all things brain health, including burnout and wellness issues.

Diversity, Equity, and Inclusion

Offers programs that relate to DEI issues, including health care disparities, women’s health, and more.

Neurohospitalists

Features related courses, presentations, and networking opportunities of specific interest to neurohospitalists.

Neurology Education

Elevate your education with courses and networking opportunities specifically geared towards educators.

Spanish Language

Comprised of seven programs delivered entirely in Spanish, as well as other Spanish-language networking opportunities.

Visit www.aan.com/events/annual-meeting-targeted-interests to see each interest lineup.

Get Ready for Tuesday’s Run/Walk to Help Raise Money for Research

If you signed up for the 5K Run/Walk for Brain Research, now is the time to get excited! This popular Annual Meeting event will kick off bright and early Tuesday from 6:30 a.m. to 8:00 a.m. at City Park.

Pick up your t-shirt and other race materials near Registration. Thank you for helping support important neurology research!

The Run/Walk for Brain Research is sponsored by Eisai Inc, argenx, Harmony Biosciences, Xenon Pharmaceuticals, Sanofi, Viatris, Bristol Myers Squibb, and Inova Health.

Matthew N. Jaffa, DO

What’s your favorite thing about the Annual Meeting?

My favorite thing is the connection with all of my friends and colleagues from different institutions who I’ve met over the years. All the people I worked with when I was a medical student and a resident, who I hadn’t seen in many years but get to see here annually, also all the people I’m working with who I haven’t met yet—I get to see them here, in person.

Do you have any exciting memories from a previous meeting?

My first Annual Meeting—Los Angeles in 2018—was unbelievable for me because it was my first real exposure to how incredibly large our small community of neurologists actually is and to actually see the engagement of everybody in that community coming together at one time.

Maya S. Graham, MD, PhD

What do you think will be the best part of the Annual Meeting this year?

I think the best part of it for me has been being a part of the Emerging Leaders Program. I initially joined the program for my own journey—to grow as a leader. But meeting this group of people, who were like-minded neurologists interested in growing and bettering the field, has been the best part.

Progressive muscle weakness may be a sign of muscular dystrophy.

Explore sponsored no-charge genetic testing today.

Could it be a limb-girdle muscular dystrophy?

The differential diagnosis for muscle weakness is broad, with many conditions sharing the same signs and symptoms. Genetic testing is a critical step to confirming or ruling out a diagnosis.

Select overlapping symptoms that are commonly seen are shown below:

Proximal limb weakness Falls or tripping

Muscle pain and/or cramps

Calf hypertrophy

Cardiac involvement Respiratory involvement

Limb-girdle muscular dystrophies (LGMDs)*

Pompe disease

Polymyositis

Myasthenia gravis

Spinal muscular atrophy

Becker muscular dystrophy

Facioscapulohumeral muscular dystrophy

The check marks above refer to commonly identified symptoms in each condition. Some patients may still exhibit or develop a symptom even if not marked above.

*For LGMDs, different subtypes have varying degrees of cardiac and/or respiratory involvement.

Potential treatments for limb-girdle muscular dystrophies are being investigated, with several therapies currently in clinical development. Sign up to receive educational updates from Sarepta.

Intended for U.S. audiences only